Be careful out there.
Two more blood pressure medications recalled for ingredient that might cause cancer
The list of blood pressure drugs
recalled because they have NDEA grew by two Tuesday when Teva
Pharmaceuticals yanked all lots of Amlodipine/Valsartan and
Amlodipine/Valsartan/Hydrochlorothiazide combination tablets.
Both have too much N-nitroso-diethylamine (NDEA) in its Valsartan, the active ingredient made by Mylan India. NDEA has been classified as a probable cancerous ingredient by the International Agency for Research on Cancer.
More NDEA than allowed prompted Mylan’s recall of 15 heart attack and blood pressure medications last week, as well as Sandoz’s recall of Losartan blood pressure meds on Nov. 8 and July’s slew of Valsartan blood pressure drug recalls.
As with previous recalls, the company-written, FDA-posted recall notice advises continuing to take the recalled drugs until the patient and a medical professional agree on another course of action.
“The risk of harm to a patient’s health may be higher if the treatment is stopped immediately without any comparable alternative treatment,” the notice states.
Specific lots in the article.
Both have too much N-nitroso-diethylamine (NDEA) in its Valsartan, the active ingredient made by Mylan India. NDEA has been classified as a probable cancerous ingredient by the International Agency for Research on Cancer.
More NDEA than allowed prompted Mylan’s recall of 15 heart attack and blood pressure medications last week, as well as Sandoz’s recall of Losartan blood pressure meds on Nov. 8 and July’s slew of Valsartan blood pressure drug recalls.
As with previous recalls, the company-written, FDA-posted recall notice advises continuing to take the recalled drugs until the patient and a medical professional agree on another course of action.
“The risk of harm to a patient’s health may be higher if the treatment is stopped immediately without any comparable alternative treatment,” the notice states.
Specific lots in the article.
No comments:
Post a Comment